CLN-619 is under clinical development by Cullinan Oncology and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase I drugs for Metastatic Transitional (Urothelial) Tract Cancer have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CLN-619’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CLN-619 is under development for the treatment of solid tumors such as Non-small cell lung cancer, cervical cancer, head and neck cancer squamous cell carcinoma, and metastatic urothelial carcinoma. The therapeutic candidate is a anti-MICA humanized IgG1 monoclonal antibody and acts by targeting MHC class I polypeptide related sequence A (MICA) and MHC class I polypeptide related sequence B (MICB).
It was also under development for liver cancer.
Cullinan Oncology overview
Cullinan Oncology operates as a biopharmaceutical company. It focuses on the development of targeted therapeutics to treat cancer patients. The company’s product portfolio comprises CLN-081, CLN-049, CLN-619, CLN-978 and CLN-617. It offers its products in the therapeutic area of non-small cell lung cancer, acute myeloid leukemia, cancer, solid tumors and advanced malignancies. The company works in collaboration with Taiho Pharmaceutical for the development of CLN-081, Adimab LLC to generate antibody-derived binding domains specific for CD19, CD3, and HS and Fred Hutchinson Cancer Research Center. Cullinan Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of CLN-619’s drug-specific PTSR and LoA scores, buy the report here.